Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Gross Margin (2021 - 2023)

Historic Gross Margin for ADC Therapeutics (ADCT) over the last 3 years, with Q3 2023 value amounting to 5.26%.

  • ADC Therapeutics' Gross Margin fell 930400.0% to 5.26% in Q3 2023 from the same period last year, while for Sep 2023 it was 99.26%, marking a year-over-year increase of 21800.0%. This contributed to the annual value of 2181331.87% for FY2022, which is 21814273400.0% down from last year.
  • ADC Therapeutics' Gross Margin amounted to 5.26% in Q3 2023, which was down 930400.0% from 25.03% recorded in Q2 2023.
  • ADC Therapeutics' Gross Margin's 5-year high stood at 99.3% during Q4 2022, with a 5-year trough of 5.26% in Q3 2023.
  • In the last 3 years, ADC Therapeutics' Gross Margin had a median value of 96.48% in 2021 and averaged 79.9%.
  • Per our database at Business Quant, ADC Therapeutics' Gross Margin skyrocketed by 38300bps in 2022 and then crashed by -930400bps in 2023.
  • Over the past 3 years, ADC Therapeutics' Gross Margin (Quarter) stood at 95.47% in 2021, then rose by 4bps to 99.3% in 2022, then plummeted by -95bps to 5.26% in 2023.
  • Its Gross Margin stands at 5.26% for Q3 2023, versus 25.03% for Q2 2023 and 96.89% for Q1 2023.